Zhi Tong Cai Jing·2025-08-29 06:37Core Viewpoint - 泰格医药's stock fell over 3% despite the release of its 2025 interim results, indicating market concerns over its declining revenue and profit figures [1] Financial Performance - The company reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21% [1] - The net profit attributable to shareholders was 383 million yuan, down 22.22% year-on-year [1] - In Q2, revenue was 1.686 billion yuan, a slight decline of 0.69% year-on-year [1] - The net profit for Q2 was 218 million yuan, reflecting a year-on-year decrease of 15.48% [1] Market Expectations - UBS noted that the Q2 revenue decline of 0.7% to 1.69 billion yuan was less severe than the 5.8% drop in Q1, but still below expectations [1] - The net profit decline of 15.5% to 218 million yuan was also below market expectations, although it improved from a 29.6% drop in Q1 [1] Future Guidance - The company maintained its full-year guidance, expecting revenue to grow in the high single digits [1] - The gross margin is anticipated to recover quarterly, with an improvement in the recurring net profit margin [1] - Due to new order growth in Q1, the full-year revenue forecast was raised to approximately 15%, up from over 10% previously [1] - The company expects a net operating cash flow of about 1 billion yuan this year and plans to enhance shareholder returns through dividends or stock buybacks [1]